Today News Journal
    What's Hot

    Is Loughton A Good Choice For Raising A Family?

    January 31, 2023

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Today News Journal
    Contact Us
    • Home
    • Trending
    • Business
    • Health
    • Technology
      • Automobile
      • Gadgets
      • Mobiles
      • Robotics
    • Lifestyle
      • Culture
    • Sports
    • Travel
    • Editorials
    • News
      • Politics
    Today News Journal
    Home » Business » Kazia Enrols First Patient To Evt801 Phase I Clinical Trial
    Business

    Kazia Enrols First Patient To Evt801 Phase I Clinical Trial

    Nick WilsionBy Nick WilsionNovember 5, 2021No Comments5 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.

    Key Points

    EVT801 is a small molecule inhibitor of VEGFR3, and acts by inhibiting lymphangiogenesis, the formation of new lymphatic vessels around the tumour. It has shown compelling evidence of activity in a wide range of preclinical cancer models and appears broadly well-tolerated in animal toxicology studies.
    -Kazia licensed EVT801 from Evotec SE, an international drug discovery alliance and development partnership company, in April 2021.

    The phase I study will focus primarily on understanding the safety, tolerability, and pharmacokinetics of EVT801 across a range of doses. It is also designed to explore preliminary signals of clinical efficacy, and to investigate the biological activity of the drug via a rich suite of sophisticated biomarker analyses.

    The lead clinical site in the study is L’Institut Universitaire du Cancer de Toulouse Oncopole (IUCT-Oncopole) in Toulouse, France. The lead investigator is Dr Carlos Gomez-Roca, a medical oncologist with a strong background in drug development and early phase clinical trials.

    The phase I study is expected to recruit a maximum of 60 patients, with the actual number dependent on the emergent safety profile of the drug. Timelines to completion will depend on the number of dose levels tested, and Kazia expects to provide further guidance on this as the study progresses.

    Dr Carlos Gomez-Roca commented, “We are pleased to now be enrolling patients to this phase I study of EVT801. Despite great progress in the treatment of cancer over recent years, there remains a substantial need for new therapeutic options in a wide range of tumours. EVT801 has shown promising preclinical data, and we very much hope that it may now prove beneficial to our patients.

    Kazia CEO, Dr James Garner, added, “in the six months since we licensed EVT801, the Kazia and Evotec teams have been working assiduously to execute a first-in-human study of this very promising drug candidate. It has been a privilege to work with the team at the IUCT-Oncopole site in Toulouse, which is one of the leading cancer centres in France, and we hope to add an additional centre in the new year. We are delighted that the study is now open to recruitment. All of us in Kazia firmly believe that EVT801 has enormous potential as a novel cancer therapy, and we look forward to working closely with the investigators to explore that potential.

    Dr Cord Dohrmann, Chief Scientific Officer of Evotec SE, said, “We are very excited to see EVT801 proceed to the clinic. The Phase I clinical trial will be conducted by Evotec, under the sponsorship of Kazia, at the renowned IUCT-Oncopole in Toulouse. Evotec will support the management of the Phase I clinical trial with analyses and biomarker development, which we anticipate will yield important data for the validation of the approach and to further contribute to the development of robust patient stratification strategies for the further clinical evaluation of EVT801.

    Phase I Study Design

    The phase I study of EVT801 is designed in two stages. The first stage is a multiple ascending dose (MAD) study, which is designed to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for EVT801. Patients in the study will receive EVT801 at low doses, and this will be progressively escalated in subsequent cohorts as the safety profile of the drug is determined.

    The second stage of the study will recruit twelve patients, of whom six will have been diagnosed with renal cell carcinoma and six with soft-tissue sarcoma. All twelve patients will receive EVT801 at the RP2D determined in the first stage. These patients will participate in intensive analyses to better understand the biochemical activity of the drug.

    In addition to conventional measures of safety, efficacy, and pharmacokinetics, the phase I study will employ cutting edge biomarker technologies to provide early insights into the activity of EVT801. A rich program of tissue and blood biomarker analyses has been developed by Evotec scientists, in collaboration with the team at Oncopole. It is expected that these analyses will help to better understand the effects of the drug in human subjects and may also help to identify the most responsive patients and provide early predictors of clinical efficacy.

    Kazia is also collaborating with Radiomics, an imaging analysis organisation based in Belgium, to apply sophisticated AI-based analyses to the CT and MRI scans collected during the study. Proprietary machine-learning algorithms developed by Radiomics can provide exceptionally detailed insights into the behaviour of the tumour while on treatment, and this information may help to predict and understand clinical response.

    Clinical Sites

    The lead site in the study is the Institut Universitaire du Cancer de Toulouse Oncopole (IUCT-Oncopole) in Toulouse, France. IUCT-Oncopole combines several leading clinical cancer treatment facilities with a world-class research infrastructure, on an integrated campus that brings together public and private stakeholders, including industry participants. The centre treats more than 10,000 new patients each year, and more than one in eight patients are enrolled in clinical studies.

    The lead investigator for the study is Dr Carlos Gomez-Roca, medical oncologist and Chair of the Early Phase Unit at IUCT-Oncopole, Dr Gomez-Roca’s clinical research is focused on development of targeted therapies and immuno-oncology drugs. He is a member of ESMO, ASCO, FITC and AACR, and has contributed to more than 60 peer-reviewed publications, including as first or second author, in journals such as the Journal of Clinical Oncology and Annals of Oncology.

    Source Kazia Therapeutics Limited

    Related posts:

    1. BitMEX Confirms It Has Reached Settlements With CFTC And FinCEN
    2. Cambridge English Gets Quality Endorsement From Australia’s Neas
    3. Pepperstone Group Is Pleased To Announce The Appointment Of David Shafer To Serve As A Board Advisor
    4. PR Newswire’s Business & Finance Media Pitching Kit 2021 (APAC Edition) Shares News and Trends on the Radar of Journalists
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleRiddle 3 Pty Ltd (and Others) Announce The Offering of Fully Drawn Secured Loan Notes
    Next Article Rapyd Unveils “B2b Payments Infrastructure Of The Future” To Support Global B2b Commerce And Trade Platforms
    Nick Wilsion
    • Website

    Related Posts

    Is Loughton A Good Choice For Raising A Family?

    January 31, 2023

    A Brief Introduction To Local SEO Citation

    April 28, 2022

    Tips To Hire Blogger Outreach Companies In The UK

    April 25, 2022

    Everything You Need To Know About Niche Edits

    April 22, 2022

    Leave A Reply Cancel Reply

    Search
    Categories
    • Automobile
    • Business
    • Coronavirus
    • Culture
    • Editorials
    • Finance
    • Gadgets
    • Health
    • Lifestyle
    • Mobiles
    • Money
    • News
    • Politics
    • Sports
    • Technology
    • Travel
    • Trending
    • World
    Latest Posts

    Is Loughton A Good Choice For Raising A Family?

    January 31, 2023

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023

    Pediatricians are giving out free gun locks to approach the gun violence epidemic as a public health crisis

    January 25, 2023
    • Facebook
    • Twitter
    Don't Miss
    Business

    Is Loughton A Good Choice For Raising A Family?

    By James MartinJanuary 31, 20230

    Loughton is a town in England that has become popular amongst expats from different corners…

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023

    Pediatricians are giving out free gun locks to approach the gun violence epidemic as a public health crisis

    January 25, 2023
    • Facebook
    • Twitter
    About Us

    Hello friends, I am James Martin. Welcome to my blog todaynewsjournal.com. We are a team of experienced journalists who are passionate about delivering the latest news and current events to our readers. Our editorial team is dedicated to providing the most accurate and up-to-date information possible. We aim to be your go-to source for news and current events. Here on this site, You will get up to date information regarding all important categories like business ideas, health tips,... (Read More)

    Latest News

    Is Loughton A Good Choice For Raising A Family?

    January 31, 2023

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023
    SIGN UP NEWSLETTER

    Join The Conversation sign up to receive emails for The Daily special tips general info.

      Facebook Twitter Instagram Pinterest
      • Home
      • Editorials
      • Get In Touch

      Copyright © 2021-2023 · Today News Journal Privacy Policy

      Type above and press Enter to search. Press Esc to cancel.

      We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
      Cookie SettingsAccept All
      Manage consent

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
      Necessary
      Always Enabled
      Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
      CookieDurationDescription
      cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
      cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
      cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
      cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
      cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
      viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
      Functional
      Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
      Performance
      Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
      Analytics
      Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
      Advertisement
      Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
      Others
      Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
      SAVE & ACCEPT

      Sign In or Register

      Welcome Back!

      Login to your account below.

      Lost password?